CEO Keeps Gobbling Up Shares

Dear Undefined, If you feel like you’ve missed out on the stock market rally… Don’t worry, I have something that may cheer you up... You see, I’ve just discovered a pharma stock… Which I believe is poised for 10X returns or higher… Before you write me off as crazy… Allow me to share with you a few details about why I believe this is a slam dunk. Reason #1: Upcoming Catalyst The FDA just authorized one of its drugs to be tested on COVID-19 patients… As of now, there is no cure for COVID and no vaccine in sight. The only way to combat the deadly virus right now is through treatment… With a Phase 2 trial on the way… My latest Sniper Report Alert… A $2 pharma stock… Could be poised for a massive breakout. Reason #2: CEO Can’t Get His Hands On Enough Shares Well before the FDA announcement was released… This company’s CEO was buying up shares like a mad man. - In May he bought 750K shares - In April he bought 2.1M shares - In March he bought 1M shares Now let me ask you something? Who do you think knows more about a company… The CEO who has put his money where his mouth is… ….owning millions of shares… Or Wall Street analysts? Which points me to the next reason why I’m dying to jump in… Reason #3: Wall Street Hates This Stock More than 25% of the existing shares are short this stock. Why should you care? Well, when a stock is heavily shorted, and the stock begins to take off… Let’s say it happens off a favorable FDA catalyst… Then everyone who borrowed the stock will most likely be forced to cover… Adding further buying pressure...and accelerating the stock up even higher… That’s why they call it a “short squeeze” Of course, I could tell you more about this stock… And how it has an established relationship with the fourth-largest drug maker in the world… But the reality is… we’re running out of time here. You see, I’m not waiting for the catalyst to hit before I enter… I want to get in before the substantial move happens. It’s the same strategy I’ve applied to help me make $1.2M in trading profits in 2020… And hundreds of winners along the way... But you know what? This isn’t one of those high-priced stocks that very few people can get involved in… Not at all… I’m talking about a $2 stock with the potential to go to $10…$15...or even higher… What’s even crazier...this stock also has options… Which means exponential returns are not out of the question… Look… There is only one way to get this alert. [Subscribe to the Sniper Report.]( Your subscription not only gets you access to this alert… But also 12-months of my highest conviction catalyst swing trade ideas. Ideas that I’m putting my own money behind… I don’t want this trade to slip away from me… Nor do I want to pay up to get shares… This may be the last time you hear from me about this... [But you can have all the details as soon as it drops.]( I’ve been trading biotech and pharma stocks for years now… There’s nothing I’ve seen in recent memory… That’s offered such a favorable risk-reward setup. Act now to receive my alert, detailed report, and trading plan… [Once it drops.]( [This could be the trade people talk about for years...]( Kyle Dennis [Special]( RagingBull, LLC 62 Calef Hwy. #233, Lee, NH 03861 [Click Here to stop receiving emails from kyle@biotechbreakouts.com]( [Unsubscribe from all RagingBull emails]( Neither Kyle Dennis nor RagingBull.com, LLC (publisher of BiotechBreakouts) is registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. The owners, employees and writers of RagingBull.com may engage in securities trading that is discussed or viewed on this website, but all such individuals are buying and selling such securities for their own account. These individuals do not engage in any trades with customers. The buying and selling of securities by these individuals is not part of a regular business of buying and selling securities. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for RagingBull.com, LLC may have long or short positions in securities that may be discussed on this website or newsletter, but all such positions are held for such representative’s own account. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are actual figures from the portfolios Kyle Dennis manages on behalf of RagingBull.com, LLC. If you have a current active subscription with Biotech Breakouts you will need to contact us here if you want to cancel your subscription. Opting out of emails does not remove you from your service at BiotechBreakouts.com.